Literature DB >> 11370992

Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia.

S P Mahadik1, D Evans, H Lal.   

Abstract

1. Schizophrenia is a major mental disorder that has a lifetime risk of 1% and affects at young age (average age at the onset 24 +/- 4.6 years) in many cultures around the world. The etiology is unknown, the pathophysiology is complex, and most of the patients need treatment and care for the rest of their lives. 2. Cellular oxidative stress is inferred from higher tissue levels of reactive oxygen species (ROS, e.g., O2*-, OH*, OH-, NO* and ONOO--) than its antioxidant defense that cause peroxidative cell injury, i.e., peroxidation of membrane phospholipids, particularly esterified essential polyunsaturated fatty acids (EPUFAS), proteins and DNA. 3. Oxidative stress can lead to global cellular with predominantly neuronal peroxidation, since neurons are enriched in highly susceptible EPUFAs and proteins, and damages DNA is not repaired effectively. 4. Such neuronal peroxidation may affect its function (i.e., membrane transport, loss of mitochondrial energy production, gene expression and therefore receptor-mediated phospholipid-dependent signal transduction) that may explain the altered information processing in schizophrenia. 5. It is possible that the oxidative neuronal injury can be prevented by dietary supplementation of antioxidants (e.g., vitamins E, C and A; beta-carotene, Q-enzyme, flavons, etc.) and that membrane phospholipids can be corrected by dietary supplementation of EPUFAs. 6. It may be that the oxidative stress is lower in populations consuming a low caloric diet rich in antioxidants and EPUFAs, and minimizing smoking and drinking. 7. Oxidative stress exists in schizophrenia based on altered antioxidant enzyme defense, increased lipid peroxidation and reduced levels of EPUFAs. The life style of schizophrenic patients is also prooxidative stress, i.e., heavy smoking, drinking, high caloric intake with no physical activity and treatment with pro-oxidant drugs. 8. The patients in developed countries show higher levels of lipid peroxidation and lower levels of membrane phospholipids as compared to patients in the developing countries. 9. Initial observations on the improved outcome of schizophrenia in patients supplemented with EPUFAs and antioxidants suggest the possible beneficial effects of dietary supplementation. 10. Since the oxidative stress exists at or before the onset of psychosis the use of antioxidants from the very onset of psychosis may reduce the oxidative injury and dramatically improve the outcome of illness.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11370992     DOI: 10.1016/s0278-5846(00)00181-0

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  38 in total

1.  Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study.

Authors:  Hui-chun Li; Qiao-zhen Chen; Ying Ma; Jun-fu Zhou
Journal:  J Zhejiang Univ Sci B       Date:  2006-12       Impact factor: 3.066

2.  Oxidative stress in early stage Bipolar Disorder and the association with response to lithium.

Authors:  Rafael T de Sousa; Carlos A Zarate; Marcus V Zanetti; Alana C Costa; Leda L Talib; Wagner F Gattaz; Rodrigo Machado-Vieira
Journal:  J Psychiatr Res       Date:  2013-12-06       Impact factor: 4.791

Review 3.  The Role of Nutrients in Protecting Mitochondrial Function and Neurotransmitter Signaling: Implications for the Treatment of Depression, PTSD, and Suicidal Behaviors.

Authors:  Jing Du; Ming Zhu; Hongkun Bao; Bai Li; Yilong Dong; Chunjie Xiao; Grace Y Zhang; Ioline Henter; Matthew Rudorfer; Benedetto Vitiello
Journal:  Crit Rev Food Sci Nutr       Date:  2016-11-17       Impact factor: 11.176

4.  Omega-3 fatty acid supplementation decreases DNA damage in brain of rats subjected to a chemically induced chronic model of Tyrosinemia type II.

Authors:  Milena Carvalho-Silva; Lara M Gomes; Giselli Scaini; Joyce Rebelo; Adriani P Damiani; Maiara Pereira; Vanessa M Andrade; Fernanda F Gava; Samira S Valvassori; Patricia F Schuck; Gustavo C Ferreira; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2017-03-18       Impact factor: 3.584

5.  Preventive Effect of Cecropia pachystachya Against Ketamine-Induced Manic Behavior and Oxidative Stress in Rats.

Authors:  Marta Gazal; Fernanda N Kaufmann; Bruna A Acosta; Pathise Souto Oliveira; Matheus R Valente; Caroline Flach Ortmann; Régis Sturbelle; Claiton L Lencina; Francieli M Stefanello; Manuella P Kaster; Flávio Henrique Reginatto; Gabriele Ghisleni
Journal:  Neurochem Res       Date:  2015-05-22       Impact factor: 3.996

6.  Biomarkers and clinical staging in psychiatry.

Authors:  Patrick McGorry; Matcheri Keshavan; Sherilyn Goldstone; Paul Amminger; Kelly Allott; Michael Berk; Suzie Lavoie; Christos Pantelis; Alison Yung; Stephen Wood; Ian Hickie
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

7.  Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls.

Authors:  Suzanne Medema; Roel J T Mocking; Maarten W J Koeter; Frédéric M Vaz; Carin Meijer; Lieuwe de Haan; Nico J M van Beveren; René Kahn; Lieuwe de Haan; Jim van Os; Durk Wiersma; Richard Bruggeman; Wiepke Cahn; Carin Meijer; Inez Myin-Germeys
Journal:  Schizophr Bull       Date:  2015-09-18       Impact factor: 9.306

8.  Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats.

Authors:  Santhrani Thaakur; G Himabindhu
Journal:  J Neural Transm (Vienna)       Date:  2009-05-15       Impact factor: 3.575

Review 9.  Clinical potential of omega-3 fatty acids in the treatment of schizophrenia.

Authors:  Robin Emsley; Piet Oosthuizen; Susan J van Rensburg
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia.

Authors:  Om Prakash Singh; Indranil Chakraborty; Anindya Dasgupta; Subinay Datta
Journal:  Indian J Psychiatry       Date:  2008-07       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.